Performance Status and Comorbidity Predict Transplant-Related Mortality After Allogeneic Hematopoietic Cell Transplantation
Open Access
- 30 September 2006
- journal article
- clinical trial
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 12 (9) , 954-964
- https://doi.org/10.1016/j.bbmt.2006.05.015
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Pre-transplant ganciclovir and post transplant high-dose valacyclovir reduce CMV infections after alemtuzumab-based conditioningBone Marrow Transplantation, 2006
- Comorbidity and beyond: pre-transplant clinical assessmentBone Marrow Transplantation, 2005
- Comorbidity indices in hematopoietic stem cell transplantation: a new report cardBone Marrow Transplantation, 2005
- Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of ageBlood, 2005
- Long-term follow-up of nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma: The University of Chicago ExperienceBone Marrow Transplantation, 2004
- The importance of classifying initial co-morbidity in evaluating the outcome of diabetes mellitusPublished by Elsevier ,2004
- Possibility of long-term remission in patients with advanced hematologic malignancies after reduced intensity conditioning regimen (RIC) and allogeneic stem cell transplantationThe Hematology Journal, 2004
- Congestive heart failure despite normal left ventricular systolic function in a population-based sample: the Strong Heart Study∗∗The views expressed in this study are those of the authors and do not necessarily reflect those of the Indian Health Service.The American Journal of Cardiology, 2000
- Validation of a combined comorbidity indexJournal of Clinical Epidemiology, 1994
- A new method of classifying prognostic comorbidity in longitudinal studies: Development and validationJournal of Chronic Diseases, 1987